explore -WSS

explore

author：hotspot 2025-09-30 00:09:36 - browse：6

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

Scientists at the Food and Drug Administration have two big questions about Eli Lilly’s experimental Alzheimer’s drug donanemab ahead of a panel of outside experts that it is convening on Monday:

Should the patients who receive the medicine be limited based on PET scans of a protein called tau that Eli Lilly used as a key criteria for trying to determine whether they should receive the drug? That could reduce usage of the medicine by adding a barrier to its use.

And how do the potential risks of using the drug compare to its benefits? The FDA points to one analysis, admittedly with missing data, that could indicate patients who receive the drug have a higher risk of dying.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Congress must reauthorize a committee to support older Americans

hotspot

explore

WSS

Wegovy improves function in certain heart failure patients

As obesity drug market grows, telehealth companies court payers

Readout LOUD podcast: A CRISPR milestone, biotech mixology

PBM reforms clear House panel

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Kellogg’s is going to war over Mexico’s nutrition label rules

focus

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

People can get long Covid without testing positive for virus: Study

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

DeSantis wants to import drugs. Biden’s FDA blasted his plan

Sports medicine is finally prioritizing gender equality

Intellia plays down concerns on accidental germline transmission

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Hepatitis C has a cure — but many Americans still lack access to it

CRISPR pioneers react to Casgevy, first gene

hotspot

In key trial, Verve's treatment lowers cholesterol levels in patients

Congress must reauthorize a committee to support older Americans

DeSantis wants to import drugs. Biden’s FDA blasted his plan

How the drug

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

What past blockbusters can tell us about future of Wegovy and other weight loss medicines

explore

hotspot

explore

hotspot